Dyne Therapeutics prices upsized $375M public offering of 18.3M shares at $20.50/share

Dyne Therapeutics, Inc.

Offering of 18,300,000 shares at $20.50/share; gross proceeds $375.15M.
Net proceeds estimated at $352.1M, or $405.0M if underwriters' option exercised.
Underwriters granted 30-day option to purchase up to 2,745,000 additional shares.
Closing expected July 23, 2026; proceeds extend cash runway into Q2 2028.
Morgan Stanley, Jefferies, Evercore ISI, LifeSci Capital, Raymond James are joint book-runners.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.